Compare Bristol-Myers Squibb Co (BMY) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs abrdn Physical Palladium Shares ETF — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while abrdn Physical Palladium Shares ETF trades at $23.52. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while abrdn Physical Palladium Shares ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| BMY | PALL | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $62.37 | $37.18 |
52-Week Low | $42.60 | $19.96 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
PALL (abrdn Physical Palladium Shares ETF) trades at $22.73, down 1.47% with bearish technical signals from moving averages. The ETF faces headwinds from palladium's 47% price decline from January 2026 highs, though recent news highlights potential buying opportunities as the metal approaches technical support levels. A 1:5 stock split occurred on May 18, 2026, which adjusted share count without changing the fund's total value.
The outlook remains cautious due to weak palladium pricing and industrial demand concerns, though some analysts see value at current levels. Key risks include commodity price volatility and Federal Reserve policy impacts. Investment appeal hinges on palladium's supply-demand dynamics improving from current depressed conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
